| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-79 |
Sentence |
denotes |
Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. |
| T2 |
80-266 |
Sentence |
denotes |
Sphingosine has been shown to prevent and eliminate bacterial infections of the respiratory tract, but it is unknown whether sphingosine can be also employed to prevent viral infections. |
| T3 |
267-557 |
Sentence |
denotes |
To test this hypothesis, we analyzed whether sphingosine regulates the infection of cultured and freshly isolated ex vivohuman epithelial cells with pseudoviral particles expressing SARS-CoV-2 spike (pp-VSV-SARS-CoV-2 spike) that served as a bona fide system mimicking SARS-CoV-2 infection. |
| T4 |
558-686 |
Sentence |
denotes |
We demonstrate that exogenously applied sphingosine suspended in 0.9% NaCl prevents cellular infection with pp-SARS-CoV-2 spike. |
| T5 |
687-888 |
Sentence |
denotes |
Pre-treatment of cultured Vero epithelial cells or freshly isolated human nasal epithelial cells with low concentrations of sphingosine prevented adhesion of and infection with pp-VSV-SARS-CoV-2 spike. |
| T6 |
889-1087 |
Sentence |
denotes |
Mechanistically, we demonstrate that sphingosine binds to ACE2, the cellular receptor of SARS-CoV-2, and prevents the interaction of the receptor binding domain of the viral spike protein with ACE2. |
| T7 |
1088-1232 |
Sentence |
denotes |
These data indicate that sphingosine prevents at least some viral infections by interfering with the interaction of the virus with its receptor. |
| T8 |
1233-1423 |
Sentence |
denotes |
Our data also suggest that further preclinical and finally clinical examination of sphingosine is warranted for potential use as a prophylactic or early treatment for coronavirus disease-19. |
